2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176402
    Dyrk1A-IN-13 99.43%
    Dyrk1A-IN-13 (Compound 1) is a DYRK1A inhibitor (IC50: 41 nM). Dyrk1A-IN-13 reduces LPS-induced NO production and has antioxidant and anti-inflammatory activities. Dyrk1A-IN-13 can be used in the research of Alzheimer's disease, cancer and diabetes.
    Dyrk1A-IN-13
  • HY-176487
    SARM1-IN-6 3080315-51-8 98%
    SARM1-IN-6 (Compound 22b) is a brain-permeable SARM1 orthosteric inhibitor, the IC50 of SARM1-IN-6 against NAM is 0.069 μM.
    SARM1-IN-6
  • HY-176515
    Cipepofol glucuronide 3118400-26-0 99.92%
    Cipepofol glucuronide (Ciprofol Glucuronide) (M4) is a glucuronide metabolite of Ciprofol (HY-116152). Cipepofol glucuronide has no significant inhibitory activity toward P450s and UDP-glucuronosyltransferases (UGTs), and it has a lower risk of acting as a perpetrator for drug-drug interactions (DDIs). Cipepofol glucuronide can be used for anesthesia research.
    Cipepofol glucuronide
  • HY-176540
    Microtubule stabilizer-1 2699937-76-1 99.47%
    Microtubule stabilizer-1 (compound 69) is a brain-penetrant microtubule (MT) stabilizer. Microtubule stabilizer-1 increases acetylated α-tubulin (AcTub) levels and prevents the characteristic loss of neuronal MTs that is observed after incubation with Okadaic acid (HY-N6785). Microtubule stabilizer-1 can be used for the study of Alzheimer’s disease (AD) and related neurodegenerative tauopathies.
    Microtubule stabilizer-1
  • HY-176892
    Papaveroline 574-77-6 98%
    Papaveroline is an orally active Fyn tyrosine kinase inhibitor. Papaveroline stably binds to the active site of Fyn tyrosine kinase via hydrogen bonding and hydrophobic interactions, thereby inhibiting kinase activity associated with the pathogenesis of Alzheimer's disease. Papaveroline can be used for the research of Alzheimer's disease.
    Papaveroline
  • HY-176911
    Nav1.8-IN-21 3049923-99-8
    Nav1.8-IN-21 is a potent and selective Nav1.8 inhibitor with analgesic activity. Nav1.8-IN-21 can be used for analgesia Research.
    Nav1.8-IN-21
  • HY-176990
    TP receptor antagonist-3 165537-72-4 99.88%
    TP receptor antagonist-3 (compound 51280) is a potent thromboxane A2 prostanoid (TP) receptor with an IC50 of 15.7 nM against Human TP. TP receptor antagonist-3 can be used for alzheimer's disease, cardiovascular and respiratory diseases, and cancer research.
    TP receptor antagonist-3
  • HY-178049
    UM-259
    UM-259 is a STING inhibitor, with an EC50 of 1.50 μM in THP1-Dual cells expressing wild-type STING. UM-259 blocks STING oligomerization and inhibits diABZI-induced phosphorylation of TBK1 and IRF3, thereby suppressing the transcription of IFNβ and IL6 and reducing IFNβ secretion. UM-259 can be used for the study of STING-dependent inflammatory and neurological diseases.
    UM-259
  • HY-178227
    KY19334 2319609-67-9 98%
    KY19334 is a CXXC5-DVL inhibitor. KY19334 can activate the Wnt/β-catenin pathway by inhibiting CXXC5-Dvl interaction. KY19334 can inhibit cancer cells proliferation, migration, invasion and transformation by inhibiting CDK1. KY19334 can accelerate wound healing and exert regenerative effects. KY19334 can be used for the researches of cancer, inflammation, metabolic and neurological disease, such as cutaneous squamous cell carcinoma and diabetes.
    KY19334
  • HY-178907
    SERT/5-HT-IN-1 3120534-54-2 98%
    SERT/5-HT-IN-1 (compound D17) is an orally active and potent dual target inhibitor of SERT/5-HT3A (SERT IC50 = 1.5 nM, NET IC50 = 49 nM, DAT IC50 = 91 nM, 5-HT3A Ki = 12 nM). SERT/5-HT-IN-1 has an IC50 of 39 nM to 5-HT3A. SERT/5-HT-IN-1 has a lower risk of liver, kidney, and cardiac toxicity. SERT/5-HT-IN-1 can be used for research on depressive disorders.
    SERT/5-HT-IN-1
  • HY-179177
    AO-365/43472821 1081122-55-5 99.94%
    AO-365/43472821 is a selective, brain-penetrant Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor (IC50 = 0.29 μM) and shows a significant inhibitory effect on (CDC-like kinase 1) CLK1 (IC50 = 0.08 μM). AO-365/43472821 could protect the human neuroblastoma cell line SH-SY5Y from Okadaic acid (HY-N6785) (OA)-induced injury. AO-365/43472821 decreased tau (pSer396)/tau and Aβ1-42 protein expression. AO-365/43472821 can be used for the study of Alzheimer's disease.
    AO-365/43472821
  • HY-179215
    OV329 hydrochloride 2093928-29-9 99.83%
    OV329 hydrochloride is a potent GABA aminotransferase inactivator. OV329 hydrochloride is a Vigabatrin (HY-15399) analogue. OV329 hydrochloride can increase brain GABA levels and block abnormal intracerebral hyperexcitability. OV329 hydrochloride exhibits anticonvulsant and antiepileptic activities. OV329 hydrochloride can be used for the research of neurological disease, such as seizure.
    OV329 hydrochloride
  • HY-179390
    KMCA-0011 99.88%
    KMCA-0011 is an orally active ɑ2C adrenoceptor antagonist (Ki = 56.7 nM). KMCA-0011 alleviates depressive behaviors by enhancing BDNF and synaptic plasticity. KMCA-0011 displays favorable metabolic stability, including high plasma stability (99.8% after 120 min). KMCA-0011 can be used for the research of depression.
    KMCA-0011
  • HY-179523
    Carba1 2635394-10-2 98.23%
    Carba1 is a bifunctional Carbazole (HY-D0204) derivative that activates nicotinamide phosphoribosyltransferase (NAMPT) and enhances NAD biosynthesis. Carba1 binds to colchicine site of tubulin, enhancing the anti-tumor effect of various chemotherapy drugs, such as Paclitaxel (HY-B0015). Carba1 exerts neuroprotective effect and can regulate cell energy metabolism. Carba1 can be used for the researches of cancer and chemotherapy-induced peripheral neuropathy (CIPN).
    Carba1
  • HY-179568
    F3288-0031 926493-93-8
    F3288-0031 is a brain-penetrant norepinephrine transporter (NET) allosteric inhibitor with inhibitory rates of 73.5% at 20 μM. F3288-0031 binds within the inner vestibule of NET, stabilizing the inward-open state and has a preferential NET/SERT inhibition with pIC50 = 5.9. F3288-0031 shows no detectable off-target functional activity in vitro. F3288-0031 demonstrates robust antidepressant-like efficacy in vivo without confounding locomotor effects, F3288-0031 can be used for depressive disorder and related neuropsychiatric conditions.
    F3288-0031
  • HY-179579
    TMU4142 98.93%
    TMU4142 is a selective 5-HT1a agonist with high GoA activity. TMU4142 has weak Gi3 activity, can elicit rapid antidepressant like effects without triggering significant activation of dorsal raphe nucleus (DRN) 5-HT1a R autoreceptors or serotonergic neuron firing. TMU4142 demonstrates fast-acting efficacy in mouse models of depression. TMU4142 can be used for antidepressants research.
    TMU4142
  • HY-179721
    CCKBR agonist-2 923714-61-8 99.81%
    CCKBR agonist-2 (Compound z-44) is a Gi-preferring CCKBR agonist. CCKBR agonist-2 effectively activates the CCKBR-Gi signaling pathway (EC50 = 0.27 nM), but has almost no activity on Gq and Gs signaling pathways. CCKBR agonist-2 shows no significant protective effect in the mouse Alzheimer's disease model, proving that the simple activation of the Gi signal pathway does not play a dominant role in the improvement of cognitive function.
    CCKBR agonist-2
  • HY-180554
    UCB1244283 300587-89-7
    UCB1244283 is a synaptic vesicle glycoprotein 2A (SV2A) allosteric modulator. UCB1244283 binds to a secondary ligand-binding site in SV2A and enhances orthosteric ligand engagement when the orthosteric site is occupied, by stabilizing the occluded state and slowing ligand dissociation. UCB1244283 shows a clear protective effect against both tonic and clonic convulsions in sound-sensitive mice. UCB1244283 can be used for epilepsy research.
    UCB1244283
  • HY-182500
    SARM1-IN-9 3020765-69-6 98.42%
    SARM1-IN-9 (Compound MY-13B) is a stereoselective SARM1 inhibitor. SARM1-IN-9 is applicable to research related to axon degeneration-dependent neurological diseases.
    SARM1-IN-9
  • HY-182638
    CPL500036 1829530-11-1
    CPL500036 is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). CPL500036 acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. CPL500036 alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. CPL500036 induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. CPL500036 can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia.
    CPL500036
Cat. No. Product Name / Synonyms Application Reactivity